| Cross-neutralizing and protective human antibody specificities to poxvirus infections I Gilchuk, P Gilchuk, G Sapparapu, R Lampley, V Singh, N Kose, DL Blum, ... Cell 167 (3), 684-694. e9, 2016 | 193 | 2016 |
| rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a … TP Monath, PE Fast, K Modjarrad, DK Clarke, BK Martin, J Fusco, ... Vaccine: X 1, 100009, 2019 | 90 | 2019 |
| Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment DK Clarke, RM Hendry, V Singh, JK Rose, SJ Seligman, B Klug, ... Vaccine 34 (51), 6597-6609, 2016 | 71 | 2016 |
| Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy Y Tang, A Chaillon, S Gianella, LM Wong, D Li, TL Simermeyer, ... The Journal of clinical investigation 133 (12), 2023 | 66 | 2023 |
| SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19 S Ravichandran, J Tang, G Grubbs, Y Lee, S Pourhashemi, L Hussaini, ... Nature Immunology 22 (11), 1452-1464, 2021 | 54 | 2021 |
| Transgender women have higher human papillomavirus prevalence than men who have sex with men—two US cities, 2012–2014 V Singh, B Gratzer, PM Gorbach, RA Crosby, G Panicker, M Steinau, ... Sexually transmitted diseases 46 (10), 657-662, 2019 | 45 | 2019 |
| Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains RC Condit, AL Williamson, R Sheets, SJ Seligman, TP Monath, JL Excler, ... Vaccine 34 (51), 6610-6616, 2016 | 44 | 2016 |
| Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States E Meites, L Stone, R Amiling, V Singh, ER Unger, CS Derkay, ... Clinical Infectious Diseases 73 (5), 885-890, 2021 | 40 | 2021 |
| Juvenile-onset recurrent respiratory papillomatosis in the United States, epidemiology and HPV types—2015–2020 R Amiling, E Meites, TD Querec, L Stone, V Singh, ER Unger, CS Derkay, ... Journal of the Pediatric Infectious Diseases Society 10 (7), 774-781, 2021 | 34 | 2021 |
| Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth JR Willis, G Sapparapu, S Murrell, JP Julien, V Singh, HG King, Y Xia, ... The Journal of clinical investigation 125 (6), 2523-2531, 2015 | 34 | 2015 |
| Disclosure of sexual behavior is significantly associated with receiving a panel of health care services recommended for men who have sex with men V Singh, RA Crosby, B Gratzer, PM Gorbach, LE Markowitz, E Meites Sexually transmitted diseases 45 (12), 803-807, 2018 | 29 | 2018 |
| Recognition of influenza H3N2 variant virus by human neutralizing antibodies S Bangaru, T Nieusma, N Kose, NJ Thornburg, JA Finn, BS Kaplan, ... JCI insight 1 (10), 2016 | 28 | 2016 |
| Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization JR Willis, JA Finn, B Briney, G Sapparapu, V Singh, H King, ... Proceedings of the National Academy of Sciences 113 (16), 4446-4451, 2016 | 28 | 2016 |
| Latency reversal 2.0: giving the immune system a seat at the table V Singh, A Dashti, M Mavigner, A Chahroudi Current HIV/AIDS Reports 18, 117-127, 2021 | 26 | 2021 |
| Limited induction of SARS-CoV-2–specific T cell responses in children with multisystem inflammatory syndrome compared with COVID-19 V Singh, V Obregon-Perko, SA Lapp, AM Horner, A Brooks, L Macoy, ... JCI insight 7 (4), 2022 | 20 | 2022 |
| Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines S Kochhar, JL Excler, K Bok, M Gurwith, MM McNeil, SJ Seligman, ... Vaccine 37 (38), 5796-5802, 2019 | 16 | 2019 |
| AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques A Dashti, S Sukkestad, AM Horner, M Neja, Z Siddiqi, C Waller, J Goldy, ... Nature Medicine 29 (10), 2535-2546, 2023 | 13 | 2023 |
| Brighton Collaboration Viral Vector Vaccines Safety Working G. rVSVDeltaG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire … TP Monath, PE Fast, K Modjarrad, DK Clarke, BK Martin, J Fusco, ... Vaccine X 1, 100009, 2019 | 9* | 2019 |
| Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth VU Chukwuma, N Kose, DN Sather, G Sapparapu, R Falk, H King, ... PLoS One 13 (12), e0209437, 2018 | 9 | 2018 |
| Significant declines in juvenile onset recurrent respiratory papillomatosis following HPV vaccine introduction in the United States E Meites, L Stone, R Amiling, V Singh, ER Unger, C Derkay Clin Infect Dis 73 (5), 885-890, 2021 | 7 | 2021 |
